The research and development agreement will develop synthetic promoters for use in immune system cells including lymphoid, myeloid and microglia cells.
Synpromics announces the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development.
In a recent article in IPT magazine, Synpromics’ founder and Chief Scientific Officer Dr. Michael L Roberts discusses the current obstacles to overcome in optimising gene therapies.
Synpromics collaborates with UCL to generate a range of synthetic gene promoters for the CNS to develop a gene therapy for Parkinson’s disease.
Synpromics Ltd, the leader in gene control, is listed by The Scotsman as one of the top 5 leading innovative companies in life sciences in Scotland. The life science sector employs more than 37,000 people across Scotland and continues to grow internationally, expected to be worth £8bn by 2025. Alison McLintock from Leyton shares her insights into five of the most innovative life sciences companies based in Scotland. Read more...